Want to see AU:ZLD full AI Analyst Report?
Top Page
Zelira Therapeutics
(Sydney:ZLD)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.47
▲(39.12% Upside)
Action:Downgraded
Date:02/25/26
The score is held down primarily by very weak financial performance (sharp revenue decline, ongoing losses, negative equity, and negative cash flows). Technical indicators also lean bearish (below key short-term averages and negative MACD), while valuation signals are constrained by a negative P/E and lack of dividend yield data.
Positive Factors
Focused product pipeline
A clear strategic focus on cannabinoid-based therapeutics and consumer health concentrates R&D and commercial efforts. Over the next several months this helps build domain expertise, regulatory know‑how and product differentiation that support durable commercialization pathways.
Negative Factors
Severe revenue decline
A near-total collapse in revenue undermines the firm's ability to sustain operations and invest in commercialization. Over months this erodes market presence, weakens bargaining power with partners and distributors, and increases reliance on external financing or restructuring.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused product pipeline
A clear strategic focus on cannabinoid-based therapeutics and consumer health concentrates R&D and commercial efforts. Over the next several months this helps build domain expertise, regulatory know‑how and product differentiation that support durable commercialization pathways.
Read all positive factors
Zelira Therapeutics (ZLD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.95M
Dividend YieldN/A
Average Volume (3M)1.92K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding13,147,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zelira Therapeutics Business Overview & Revenue Model
Company Description
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ b...
How the Company Makes Money
Zelira Therapeutics generates revenue primarily through the sale of its proprietary cannabinoid-based products, which are marketed to both consumers and healthcare providers. The company also engages in partnerships and collaborations with other p...
Zelira Therapeutics Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
15
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 656.00 | 94.95K | 301.12K | 1.54M | 663.32K |
| Gross Profit | -802.95K | 10.28K | -3.22M | -5.72M | -39.16K |
| EBITDA | -4.17M | -36.44M | -6.79M | -13.06M | -9.41M |
| Net Income | -3.63M | -36.57M | -5.57M | -11.95M | -8.55M |
Balance Sheet | |||||
| Total Assets | 1.30M | 5.18M | 33.89M | 37.70M | 39.37M |
| Cash, Cash Equivalents and Short-Term Investments | 5.66K | 586.16K | 146.21K | 2.75M | 4.97M |
| Total Debt | 2.14M | 5.95M | 437.90K | 500.91K | 551.08K |
| Total Liabilities | 5.59M | 9.36M | 2.18M | 2.01M | 1.54M |
| Stockholders Equity | -4.46M | -4.51M | 31.80M | 35.20M | 37.83M |
Cash Flow | |||||
| Free Cash Flow | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Operating Cash Flow | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Investing Cash Flow | 1.15M | 919.74K | 2.83M | -207.78K | 1.38M |
| Financing Cash Flow | 3.19M | 3.92M | 1.77M | 7.10M | 10.53M |
Zelira Therapeutics Technical Analysis
Negative
0.34
Price Trends
0.50
Positive
0.50
Negative
0.47
Positive
Market Momentum
>-0.01
Negative
38.51
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZLD, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.50, and below the 200-day MA of 0.47, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.51 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ZLD.
Zelira Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$163.55M | -7.59 | -134.14% | ― | ― | -64.71% | |
48 Neutral | AU$133.16M | -15.86 | -100.58% | ― | ― | -9.57% | |
45 Neutral | AU$57.11M | -14.78 | -104.56% | ― | ― | 57.89% | |
45 Neutral | AU$65.62M | -0.54 | -131.13% | ― | 2086.71% | -116.20% | |
43 Neutral | AU$99.42M | -1.96 | -265.55% | ― | -26.58% | -100.90% | |
39 Underperform | AU$5.95M | -1.56 | 56.41% | ― | ― | ― |
* Healthcare Sector Average
AU:ZLD
Zelira Therapeutics
0.50
0.08
19.05%
AU:ACW
Actinogen Medical
0.04
0.02
83.33%
AU:ENP
Tryptamine Therapeutics
0.03
<0.01
9.68%
AU:PAR
Paradigm Biopharmaceuticals
0.18
-0.25
-58.33%
AU:ILA
Island Pharmaceuticals Ltd
0.48
0.33
220.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.03
-0.12
-82.76%
Zelira Therapeutics Corporate Events
ASX Sets Deadlines for Long-Term Suspended Companies Facing Delisting Risk
Jul 10, 2026
The ASX has issued a market announcement listing entities whose securities have been suspended from trading for more than three months, detailing for each the outstanding periodic financial and activity reports and the deadlines by which these doc...
Zelira Director Converts Convertible Notes, Boosting Equity Stake
Jul 2, 2026
Zelira Therapeutics has disclosed a change in director Osagie Imasogie’s interests following the conversion of a portion of his convertible notes into ordinary shares. Imasogie acquired 1,250,000 shares at US$0.40 per share through note conv...
Zelira Therapeutics Ceases 2.25 Million Convertible Notes
Jul 2, 2026
Zelira Therapeutics has notified the market of the cessation of 2,250,000 ZLDAM convertible notes, effective 29 June 2026, under an Appendix 3H filing. The removal of these convertible notes alters the company’s issued capital profile and ma...
Zelira Therapeutics Seeks ASX Quotation for 1.25 Million New Shares
Jul 1, 2026
Zelira Therapeutics has applied for quotation on the ASX of 1,250,000 new fully paid ordinary shares, which were issued on July 1, 2026. The additional securities expand the company’s quoted share capital, potentially improving liquidity in ...
Zelira’s HOPE 1 SPV Secures Transformative US$33m Funding Commitments
Apr 29, 2026
Zelira Therapeutics has advanced funding plans for its HOPE® 1 special purpose vehicle, with definitive agreements in place for a US$32.98 million capital raising that values the SPV at about US$65.96 million and Zelira’s diluted stake ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.